{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
sulfisoxazole acetyl
to a specific field?
Status:
Investigational
Source:
INN:tauroselcholic acid [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00743925: Phase 2 Interventional Completed Acute Coronary Syndrome
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Varespladib (LY315920; A-001) is a potent and selective inhibitor of IIa, V, and X isoforms of human non-pancreatic secretory phospholipase A2 with nM IC50. The molecule acts as an anti-inflammatory agent by disrupting the first step of the arachidonic acid pathway of inflammation. Varespladib methyl is being developed by Anthera Pharmaceuticals Inc for the potential treatment of coronary artery disease, acute coronary syndrome and inflammation. Varespladib methyl is a prodrug that is rapidly metabolized to varespladib, and both compounds are able to potently inhibit the enzymes of the human secretory phospholipase groups. Phase II clinical trials of varespladib methyl in patients with coronary artery disease, rheumatoid arthritis, asthma and ulcerative colitis revealed that the drug was well tolerated. Varespladib methyl did not demonstrate a good efficacy profile in patients with rheumatoid arthritis, asthma and ulcerative colitis; whereas in patients with coronary artery disease, varespladib methyl consistently reduced LDL-cholesterol levels, (elevated LDL-cholesterol levels are a marker of increased cardiovascular risk). Varespladib methyl could represent a novel therapy for the treatment of cardiovascular disease, although the efficacy, safety profile and advantages of this drug compared with existing therapeutic options would need to be established in upcoming phase III trials.
Status:
Investigational
Source:
NCT00272961: Phase 2 Interventional Terminated Resistant Hypertension
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02723201: Phase 1 Interventional Completed Healthy
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Class (Stereo):
CHEMICAL (RACEMIC)
Cinepaxadil is cinnamoyl-piperazine derivative developed by Delalande SA for treatment cardiovascular system disorders. Cinepaxadil decrease dogs cardiac activity after i.v. administration.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Carabersat is an anticonvulsant devoid of cardiovascular side effects with minimal central nervous system adverse actions. Carabersat does not bind to ion channels, purinergic, aminergic, opioid and other peptidergic receptors. It selectively interacts with its own binding site, which is not yet elucidated. Carabersat has no effect on sodium channels, GABAergic or glutamate pathways. Carabersat had been in phase II clinical trials for the treatment of epilepsy. It has a potential action in preventing migraines because it acts through an inhibition of the cortical spreading depression trigeminal nerve-induced vasodilatation in cats. Its good therapeutic index and the markedly reduced neurological impairments could make it a useful agent for migraine prophylaxis pending efficacy parameters of controlled studies, which are underway.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Salmisteine was studied as an antipyretic and mucolytic agent. Information about the current use of this compound is not available.
Class (Stereo):
CHEMICAL (ACHIRAL)
Darenzepine is an antagonist of muscarinic receptors, developed by at Knoll/BASF Pharma. It is claimed to have antiulcer effect superior to pirenzepine and to have less anticholinergic adverse effects.
Status:
Investigational
Source:
INN:piridicillin [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Piridicillin is the semi-synthetic penicillin. It has exhibited broad-spectrum activity in vitro against gram-positive cocci, except penicillin G-resistant Staphylococcus aureus, and against gram-negative bacilli. Piridicillin is reported to be more active in-vitro than piperacillin, azlocillin or ticarcillin against Ps. aeruginosa. It is unstable at alkaline pH and displays marked inoculum independence.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Mofoxime is a phenoxyalkylcarboxylic acid derivative patented by Orchimed S. A. as a neurotropic and anti-inflammatory compound.
